Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
CYSTOGRAFIN (diatrizoate meglumine) is a urographic contrast agent administered via urethral instillation to visualize the urinary tract during diagnostic imaging procedures. It is a small-molecule iodinated organic compound that provides radiographic contrast for cystography and retrograde urethrography. The drug enables visualization of bladder and urethral anatomy by increasing radiodensity in the urinary system.
As a legacy diagnostic agent approaching loss of exclusivity, CYSTOGRAFIN faces moderate competitive pressure (30/100) with limited commercial expansion opportunities and likely consolidating team structures.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
CYSTOGRAFIN offers limited career growth opportunities given its LOE-approaching status, legacy positioning, and minimal linked job openings (0 identified). Roles on this product are primarily defensive in nature, focused on maintaining market share and managing generic transition.
Worked on CYSTOGRAFIN at Bracco? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.